February 22, 2007							
UNITED STATES							
SECURITIES AND EXCHANGE CO.	MMISSION						
WASHINGTON, D.C. 20549							
FORM 8-K							
CURRENT REPORT							
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934							
Date of Report (date of earliest event reported): February 20, 2007							
Pipex Pharmaceuticals, Inc.							
(Exact name of registrant as specified in	charter)						
Delaware							
(State or other jurisdiction of incorporation)							
01-12584	13-3808303						
(Commission File Number)	(IRS Employer Identification No.)						
3985 Research Park Drive Ann Arbor, MI 48108							
	(Address of principal executive offices and zip code)						
	(734) 332-7800						
	(Registrant s telephone number including area code)						

PIPEX PHARMACEUTICALS, INC.

Form 8-K

N/A

(Former Name and Former Address)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:

- O Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- O Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)
- O Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- O Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

	Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.					
•	20, 2007, Pipex Pharmaceuticals, Inc., a Delaware corporation (the Registrant") issued the attached press release announcing the of Daniel J. Dorman and James S. Kuo, Md., M.B.A. to the Board of Directors of the Registrant.					
Item 9.01	Financial Statements and Exhibits.					
(d)	Exhibits.					
	Exhibit 99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated February 20, 2007.					

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors;

CI	GNI	A -	LI.	ID.	$\Gamma$ C

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: February 21, 2007 Pipex Pharmaceuticals, Inc

(Registrant)

By: /s/ Steve H. Kanzer

Name: Steve H. Kanzer

Title: Chief Executive Officer

·

#### EXHIBIT INDEX

Exhibit No. Exhibits.

99.1 Press Release issued by Pipex Pharmaceuticals, Inc. dated February 20, 2007